A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.12.011

Related search